![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 1-Mar-2013[ | E-mail |
Share ] Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, March 1, 2013Most adults and children with type 1 diabetes are not in optimal glycemic control, despite advances in insulin formulations and delivery systems and glucose monitoring approaches. Critical barriers to optimal glycemic control remain. A panel of experts in diabetes management and research met to explore these challenges, and their conclusions and recommendations for how to improve care and optimize clinical decision-making are presented in a white paper in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The paper is available free on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.
Lead author Richard Bergenstal, MD, International Diabetes Center at Park Nicollet (IDC), outlines the critical issues impacting diabetes management as identified by the panel of luminaries in the field of diabetes during meetings facilitated by the IDC and funded by the Helmsley Charitable Trust. The team of authors emphasizes the critical need for standardization in the collection, reporting, visualization, and analysis of glucose monitoring data, and proposes clear and practical recommendations for implementing these solutions.
The expert panel included DTT Editor-in-Chief Satish Garg, MD, DTT Senior Editor Irl Hirsch, MD, and Andrew Ahmann, MD, Timothy Bailey, MD, Roy Beck, MD, PhD, Joan Bissen, Bruce Buckingham, MD, Larry Deeb, MD, Robert Dolin, MD, Robin Goland, MD, David Klonoff, MD, Davida Kruger, MSN, Glenn Matfin, MB ChB, MSc, Roger Mazze, PhD, Beth Olson, BAN, RN, Christopher Parkin, MS, Anne Peters, MD, Margaret Powers, PhD, Henry Rodriguez, MD, Phil Southerland, Ellie Strock, ANP-BC, William Tamborlane, MD, and David Wesley.
"Glucose monitoring is an essential part of effective diabetes management, and although it has come a long way, both health care providers and patients are frustrated that glucose data reporting has not been standardized," says Satish Garg, MD, Editor-in-Chief of the Journal and Professor of Medicine and Pediatrics at the University of Colorado Denver. "The recommendations reported in this white paper are a good first step toward improving health care outcomes in type 1 diabetes."
The white paper is accompanied by three Commentaries: one by DTT Editor-in-Chief Satish Garg, MD, one by Francine Ratner Kaufman, MD, Medtronic and Children's Hospital, Los Angeles, and one by Aaron Kowalski, PhD and Sanjoy Dutta, PhD, Juvenile Diabetes Research Foundation.
###
About the Journal
Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com
Phone: 914-740-2100 800-M-LIEBERT Fax: 914-740-2101
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 1-Mar-2013[ | E-mail |
Share ] Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News
New Rochelle, NY, March 1, 2013Most adults and children with type 1 diabetes are not in optimal glycemic control, despite advances in insulin formulations and delivery systems and glucose monitoring approaches. Critical barriers to optimal glycemic control remain. A panel of experts in diabetes management and research met to explore these challenges, and their conclusions and recommendations for how to improve care and optimize clinical decision-making are presented in a white paper in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The paper is available free on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.
Lead author Richard Bergenstal, MD, International Diabetes Center at Park Nicollet (IDC), outlines the critical issues impacting diabetes management as identified by the panel of luminaries in the field of diabetes during meetings facilitated by the IDC and funded by the Helmsley Charitable Trust. The team of authors emphasizes the critical need for standardization in the collection, reporting, visualization, and analysis of glucose monitoring data, and proposes clear and practical recommendations for implementing these solutions.
The expert panel included DTT Editor-in-Chief Satish Garg, MD, DTT Senior Editor Irl Hirsch, MD, and Andrew Ahmann, MD, Timothy Bailey, MD, Roy Beck, MD, PhD, Joan Bissen, Bruce Buckingham, MD, Larry Deeb, MD, Robert Dolin, MD, Robin Goland, MD, David Klonoff, MD, Davida Kruger, MSN, Glenn Matfin, MB ChB, MSc, Roger Mazze, PhD, Beth Olson, BAN, RN, Christopher Parkin, MS, Anne Peters, MD, Margaret Powers, PhD, Henry Rodriguez, MD, Phil Southerland, Ellie Strock, ANP-BC, William Tamborlane, MD, and David Wesley.
"Glucose monitoring is an essential part of effective diabetes management, and although it has come a long way, both health care providers and patients are frustrated that glucose data reporting has not been standardized," says Satish Garg, MD, Editor-in-Chief of the Journal and Professor of Medicine and Pediatrics at the University of Colorado Denver. "The recommendations reported in this white paper are a good first step toward improving health care outcomes in type 1 diabetes."
The white paper is accompanied by three Commentaries: one by DTT Editor-in-Chief Satish Garg, MD, one by Francine Ratner Kaufman, MD, Medtronic and Children's Hospital, Los Angeles, and one by Aaron Kowalski, PhD and Sanjoy Dutta, PhD, Juvenile Diabetes Research Foundation.
###
About the Journal
Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a sample issue may be viewed on the Diabetes Technology & Therapeutics website at http://www.liebertpub.com/dia.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com
Phone: 914-740-2100 800-M-LIEBERT Fax: 914-740-2101
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-03/mali-ngf030113.php
bats hunger games review jeff saturday jason smith jon corzine austin rivers austin rivers
No comments:
Post a Comment